Aytu BioPharma Q4 FY26 net loss narrows to USD 15,000; revenue rises 6.4% to USD 16.1 million vs Q4 FY25

Bitget2026/09/22 20:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Aytu Biopharma reported Q4 fiscal 2026 net revenue rose 6.4% to USD 16.1 million versus the year-ago quarter.
Net loss narrowed to USD 15,000, versus USD 19.82 million a year earlier.
Full-year net revenue fell 13.3% to USD 57.6 million, and net loss widened to USD 14.25 million.
EXXUA produced USD 3.94 million of Q4 net revenue, its first full quarter of launch, and USD 6.57 million for the year.
CEO Josh Disbrow said Q4 prescriptions topped 3,300, more than doubled sequentially, while June reached a record 1,261 scripts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609221605ACCESSWRNAPR_____1223174) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Aytu BioPharma Q4 FY26 net loss narrows to USD 15,000; revenue rises 6.4% to USD 16.1 million vs Q4 FY25

You may also like

Crypto prices